GlassScriptPhysician profile
Mandy Beth Black
NPI 1386049385
$8,306.26
in general payments reported to CMS, 2019-2025
37 companies · $1,729 in 2025
The $1,729 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,057 · 2022: $1,231 · 2023: $1,851 · 2024: $2,438 · 2025: $1,729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,017.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,500.56 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $717.31 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Insulet Corporation | $684.53 | 2021-2025 | Omnipod |
| Abbott Laboratories | $515.74 | 2021-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $471.41 | 2021-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $469.42 | 2021-2025 | |
| Amgen INC. | $463.35 | 2021-2025 | Evenity, Tepezza, Prolia |
| Xeris Pharmaceuticals, INC. | $403.57 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $355.50 | 2021-2025 | |
| Abbvie INC. | $280.29 | 2021-2024 | |
| Recordati_rare_diseases_inc. | $242.33 | 2021-2025 | Isturisa, Signifor Lar |
| Tandem Diabetes Care, INC. | $217.45 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sequel Med Tech, LLC | $191.63 | 2025 | Twiist |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.01 | 2021-2025 | Jardiance |
| Radius Health, INC. | $159.75 | 2023-2025 | Tymlos |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $157.81 | 2021-2024 | Tirosint, Licart, Tirosint |
| Corcept Therapeutics | $155.66 | 2021-2025 | Korlym |
| Antares Pharma, INC. | $129.79 | 2024-2025 | Xyosted |
| Mannkind Corporation | $125.53 | 2021-2025 | Afrezza |
| Ascendis Pharma Endocrinology INC | $118.57 | 2024-2025 | Yorvipath |
| Esperion Therapeutics, INC. | $113.28 | 2024 | Nexlizet, Nexletol |
| Merck Sharp & Dohme LLC | $96.07 | 2021-2022 | |
| Halozyme INC | $88.79 | 2023 | |
| Ascensia Diabetes Care US INC. | $85.16 | 2023-2024 | |
| Renalytix Ai, INC. | $50.57 | 2022-2023 | Kidneyintelx Blood Collection Convenience Kit |
| Medtronic, INC. | $48.00 | 2023-2025 | Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $47.82 | 2022 | |
| Amneal Pharmaceuticals LLC | $43.31 | 2021 | |
| Averitas Pharma INC. | $41.19 | 2024 | Qutenza |
| Janssen Pharmaceuticals, INC | $38.59 | 2022 | |
| Eusa Pharma (US) LLC | $20.07 | 2022 | |
| Embecta Corp. | $18.93 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Madrigal Pharmaceuticals | $16.78 | 2025 | Rezdiffra |
| Ultragenyx Pharmaceutical INC. | $16.65 | 2021 | |
| Pfizer INC. | $15.84 | 2024 | |
| Alexion Pharmaceuticals, INC. | $14.73 | 2024 | Strensiq |
| Intuity Medical INC | $13.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandy Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.